Provided by Tiger Fintech (Singapore) Pte. Ltd.

OKYO Pharma Limited

2.37
+0.12005.33%
Pre-market: 2.25-0.1200-5.06%08:05 EDT
Volume:812.21K
Turnover:2.01M
Market Cap:88.70M
PE:-7.38
High:2.56
Open:2.46
Low:2.25
Close:2.25
Loading ...

Goldman Small Cap Research Raises Price Target for OKYO Pharma Ltd. Amid Positive Developments

Reuters
·
11 Jun

OKYO Pharma CEO to Present Urcosimod Development at Bio International Convention

TIPRANKS
·
11 Jun

OKYO Pharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
05 May

Okyo Pharma announces FDA granted FTD to urcosimod

TIPRANKS
·
01 May

OKYO Pharma Ltd. Announces FDA Fast Track Designation for Urcosimod in Treating Neuropathic Corneal Pain

Reuters
·
01 May

FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain

GlobeNewswire
·
01 May

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain

GlobeNewswire
·
30 Apr

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod

GlobeNewswire
·
31 Mar

OKYO Pharma Seeks FDA Fast Track for Urcosimod in Treating Neuropathic Corneal Pain

TIPRANKS
·
10 Mar

OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain

GlobeNewswire
·
10 Mar

OKYO Pharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
18 Feb

H.C. Wainwright Sticks to Its Buy Rating for OKYO Pharma Limited Sponsored ADR (OKYO)

TIPRANKS
·
18 Feb

OKYO Pharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
15 Feb

Buy Recommendation for OKYO Pharma Driven by Promising Urcosimod Efficacy and Market Potential

TIPRANKS
·
15 Feb

OKYO Pharma’s Lead Asset OK-101 Receives USAN as Urcosimod

TIPRANKS
·
12 Feb

Okyo Pharma announces OK-101 officially assigned USAN, urcosimod

TIPRANKS
·
12 Feb

OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod

GlobeNewswire
·
12 Feb

OKYO Pharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Feb

Yi Chen’s Buy Recommendation on OKYO Pharma: Promising Potential of OK-101 for Neuropathic Corneal Pain Amid Financial and Regulatory Challenges

TIPRANKS
·
10 Feb

Okyo Pharma CEO purchases 10,000 shares of company

TIPRANKS
·
31 Jan